anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NOT FOR USE IN NEONATES

REGONOL ® (pyridostigmine bromide injection, USP) should be used with particular caution in patients with bronchial asthma or cardiac dysrhythmias. Transient bradycardia may occur and be relieved by atropine sulfate. Atropine sulfate should also be used with caution in patients with cardiac dysrhythmias. When large doses of pyridostigmine bromide are administered, as during reversal of muscle relaxants, prior or simultaneous injection of atropine sulfate or an equipotent dose of glycopyrrolate is advisable. Because of the possibility of hypersensitivity in an occasional patient, atropine and antishock medication should always be readily available. 

When used as an antagonist to nondepolarizing muscle relaxants, adequate recovery of voluntary respiration and neuromuscular transmission must be obtained prior to discontinuation of respiratory assistance, and there should be continuous patient observation. Satisfactory recovery may be judged by adequacy of skeletal muscle tone, respiratory measurements, and by observation of the response to peripheral nerve stimulation. A patent airway should be maintained and manual or mechanical ventilation should be continued until complete recovery of normal respiration is assured.

Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources (see PRECAUTIONS: Pediatric Use).
The laser optoacoustic imaging system described herein utilizes time-resolved measurement of profiles of laser-induced transient pressure (acoustic) waves. The pressure waves are emitted by acoustic sources preferentially generated in absorbing tissues of diagnostic interest. This technique allows visualization of absorbed light distribution in turbid, layered and heterogeneous tissues irradiated by laser pulses in vivo. The laser optoacoustic tomography can be used for the characterization of structure and properties of normal tissue, and for the detection of tissue pathological changes. The optical heterogeneities that can be imaged with the laser optoacoustic imaging system include abnormal tissues such as tumors, injured tissues, blood vessels and other layered tissues. Further, three dimensional images of organs and portions of organs can be obtained.
Flebogamma 5% DIF 1 g/kg of body weight administered via intravenous infusion on Day 1 and 20 mL/kg of body weight of normal saline solution (equivalent volume of 1 g/kg of body weight Flebogamma® 5% DIF infusions) will also be administered on a separate day, for a total dosing period of 2 consecutive days. every 4 weeks for 52 weeks. The order of 1 g/kg of body weight of Flebogamma® 5% DIF or 20 mL/kg of body weight normal saline solution infused on 2 consecutive days will be randomly determined for each participant by the Interactive Web Response System (IWRS), which will remain the same for the participant for all infusion visits during the treatment period.
Systems and methods for delivering oral administration of ATP in a manner that protects the ATP from degradation by gastric juices through enteric coating to enhance absorption into the blood stream and provide additional therapeutic benefit when compared with non-protected forms of ATP. Said systems and methods comprising a composition used for improving muscle torque and reducing muscle fatigue, said composition comprising an effective amount of ATP.  Preferably, a gastric acid secretion inhibitory coating is applied to the effective amount of ATP in a manner that protects the ATP from degradation by gastric juices. Said systems and methods effecting intracellular and extracellular ATP concentrations and increasing human performance by reducing muscle fatigue and recovery time which comprises administering an effective amount of ATP to a human. Alternatively, an effective amount of ATP may be administered sublingually, thereby avoiding exposure to gastric juices. The effective amount of ATP may be delivered by means of a tablet, granules, microgranules or powders.
PURPOSE OF REVIEW: This review aims to elucidate the multifaceted role of iron in the pathogenesis of atherosclerosis. The primary objective is to summarize recent advances in understanding how iron contributes to atherosclerosis through various cellular mechanisms. Additionally, the review explores the therapeutic implications of targeting iron metabolism in the prevention and treatment of cardiovascular diseases.
RECENT FINDINGS: A growing body of literature suggests that excess iron accelerates the progression of atherosclerosis, with the deleterious form of iron, non-transferrin-bound iron (NTBI), particularly exacerbating this process. Furthermore, iron overload has been demonstrated to play a pivotal role in endothelial cells, vascular smooth muscle cells, and macrophages, contributing to plaque instability and disease progression by promoting lipid peroxidation, oxidative stress, inflammatory responses, and ferroptosis. Iron plays a complex role in atherosclerosis, influencing multiple cellular processes and promoting disease progression. By promoting oxidative stress, inflammation, and ferroptosis, iron exacerbates endothelial dysfunction, smooth muscle cell calcification, and the formation of macrophage-derived foam cells. Targeted therapies focusing on iron metabolism have proven effective in treating atherosclerosis and other cardiovascular diseases.
PURPOSE: To provide an antiphlogistic analgesic plaster for external use containing a salt of diclofenac and cyclic org. base as an effective component which shows good releasing and absorbing property. CONSTITUTION: This plaster contains a salt of diclofenac [2-[(2,6-dichlorophenyl)- amino]-benzenacetic acid] and a cyclic org. base expressed by formula [X is (CH2 )m and m is 0 or 1, and n is 2] as the effective component by 0.1 to 5.0 wt.%. A pH controlling agent is used to control pH of the drug to 7.3 to 9.0. Further, if necessary, a thickener, moisture holding agent, excipient, antiseptic and crosslinking agent are properly compounded and kneaded. The kneaded material is then spread on a base body to produce a drug. As for the cyclic org. base expressed by the formula, hydroxyethylpyrolidine is used. As for the supporting body, for example, a laminated material of a nonwoven fabric and a plastic film is used.
A method that gives user/s of the exercise apparatus, a choice of exercise events that uses data generated in response to a dynamically engaging event, being performed or performed earlier on any apparatus. The participant/s have the option of participating in local, inter-group, and global exercise events. The users may have the choice of participating in exercise events, based on using raw or PAP data. From the access point, users will signup using (SAID), (FM), (ECSL); select an exercise event for competition or regular workout, using (ECES), and sampling studies, using (FELTS). The exercise data generated will be collected (DCAT), and sent for processing, analyzing and out putting, to application, database, and web servers such as LAS, LDBS, GAS, GDBS, GWS, and Server Banks. The results of the interactive exercise events will be posted at main web page and other web sites. The sampling data and other statistical data generated from the events will be shared with groups and other interested agencies.
Since the reintroduction of African swine fever virus (ASFV) in Europe in 2007 and its subsequent spread to Asia, wild boar has played a crucial role in maintaining and disseminating the virus. There are significant gaps in the knowledge regarding infection dynamics and disease pathogenesis in domestic pigs and wild boar, particularly at the early infection stage. We aimed to compare domestic pigs and wild boar infected intranasally to mimic natural infection with one of the original highly virulent genotype II ASFV isolates (Armenia 2007). The study involved euthanising three domestic pigs and three wild boar on days 1, 2, 3, and 5 post-infection, while four domestic pigs and four wild boar were monitored until they reached a humane endpoint. The parameters assessed included clinical signs, macroscopic lesions, viremia levels, tissue viral load, and virus shedding in nasal and rectal swabs from day 1 post-infection. Compared with domestic pigs, wild boar were more susceptible to ASFV, with a shorter incubation period and earlier onset of clinical signs. While wild boar reached a humane endpoint earlier than domestic pigs did, the macroscopic lesions were comparatively less severe. In addition, wild boar had earlier viremia, and the virus was also detected earlier in tissues. The medial retropharyngeal lymph nodes were identified as key portals for ASFV infection in both subspecies. No viral genome was detected in nasal or rectal swabs until shortly before reaching the humane endpoint in both domestic pigs and wild boar, suggesting limited virus shedding in acute infections.
The invention provides a traditional Chinese medicinal potus for preventing and treating subhealth conditions, which belongs to the technical field of science and is used for preventing and treating diseases caused by subhealth conditions. The invention further provides Chinese herbal tea. The traditional Chinese medicinal potus for preventing and treating subhealth conditions is formulated and prepared from 12 g of red ginseng, 24 g of hawthorn fruit, 18 g of Chinese wolfberry, 15 g of honeysuckle, 15 g of chrysanthemum, 12 g of licorice, 12 g of dried rehmannia root, 12 g of radix ophiopogonis, 24 g of Salvia miltiorrhiza and 24 g of puerarin. The traditional Chinese medicines are processed to form a bagged tea product through equipment. The product has the effects of removing heat and toxic substances, promoting blood flow to remove blood stasis, promoting metabolism, enhancing immunity and prolonging life. The traditional Chinese herbal tea is formulated and prepared from 120 g of red ginseng, 120 g of hawthorn fruit, 120 g of Chinese wolfberry, 120 g of honeysuckle, 120 g of chrysanthemum, 120 g of licorice, 120 g of dried rehmannia root, 120 g of radix ophiopogonis, 120 g of Salvia miltiorrhiza, 120 g of puerarin, 600 g of honey, 1000 g of white granulated sugar, an appropriate amount of sodium benzoate (antiseptic) and 33 L of purified water. The Chinese medicines are crushed and soaked, the extraction solution is separated and mixed with honey, white granulated sugar and sodium benzoate (antiseptic), and the resulting mixture is sterilized and packaged to produce the final product. The herbal tea has the effects of quenching thirst quickly, removing heat and pathogenic fire and making the skin beautiful.
Botulinum toxin A (BT-A), a potential neurotoxin produced by the bacterium Clostridium botulinum, is known for its ability to prevent the release of acetylcholine at the neuromuscular synapse, leading to temporary muscle paralysis. BT-A is used for a wide range of therapeutic applications. Several studies have shown mechanisms beyond the inhibition of acetylcholine release for pain control. BT-A inhibits the release of neurotransmitters associated with pain and inflammation, such as glutamate, CGRP, and substance P. Additionally, it would be effective in nerve entrapment leading to neuronal hypersensitivity, which is known as a new pathogenesis of painful conditions. BT-A has been applied to the treatment of a wide variety of neurological disorders. Since 2010, BT-A application has been approved and widely used as a chronic migraine prophylaxis. Moreover, due to its effects on pain through sensory modulation, it may also be effective for other headaches. Several studies using BT-A, at different doses and administration sites for headaches, have shown beneficial effects on frequency and severity. In this review, we provide an overview of using BT-A to treat primary and secondary headache disorders.
Higher coronary artery calcium (CAC) scores and progression of CAC are associated with higher mortality. We previously reported that subjects with coronary artery disease randomly allocated to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation or none had similar significant increases in CAC score over 30 months. Whether these findings are influenced by diabetes status is unknown. A total of 242 subjects with coronary artery disease who were on statin therapy were randomly allocated to to 1.86 g EPA and 1.5 g DHA daily or none (control). The CAC score was measured at baseline and 30-month follow-up using noncontrast, cardiac computed tomography. A significant interaction term between diabetes status and treatment arm was noted in the prediction of the CAC score (p <0.001). A total of 176 subjects (85.8% men) had no diabetes and 66 subjects (80.3% men) had diabetes. The mean age was 62.9 ± 7.9 versus 63.2 ± 7.1 years, respectively. The mean low-density lipoprotein cholesterol and median triglyceride levels were not significantly different between those without and with diabetes: 77.7 ± 25.9 versus 77.1 ± 30.2 mg/100 ml, respectively, and 117.0 (78.0 to 158.0) versus 119.0 (84.5 to 201.5) mg/100 ml, respectively. Subjects with diabetes on EPA+DHA had a greater increase in CAC score than subjects with diabetes in the control group (median 380.7 vs 183.5, respectively, p = 0.021). In contrast, no difference occurred between the EPA+DHA and control groups in subjects without diabetes (175.7 vs 201.1, respectively, p = 0.41). In conclusion, EPA+DHA supplementation was associated with greater CAC progression in subjects with diabetes than subjects with diabetes in the control group over a 30-month period; whether this indicates progression of the disease burden or plaque stabilization requires further study.
A computer implemented method can optimize classification of patients from large patient datasets. The method includes extracting, from data structures of different data sources, data related to a large plurality of patient. Patient electronic health record (EHR) data are linked across the data sources in a privacy preserving manner to generate patient information for the patient. Based on patient information for a selected patient, a high-cost status, a phenotype, and a persistence property of the selected patient are generated. The persistence property is one or both of a persistently high cost or a persistently high utilization. Furthermore, a high-cost status, a phenotype, and a persistence property are applied to a machine learning model to determine at least one risk score for the selected patient. The machine learning model is trained using training data related to the large plurality of patients.
A method for rapidly detecting infectious conjunctivitis in a host is provided. The method includes contacting an ocular test sample with a chromogen (e.g., Reichardt's dye) that exhibits a color change in the presence of a microbe. The present inventors have discovered that the extent of the color change may vary depending on whether the microbe is a bacteria or virus. Without intending to be limited by theory, the present inventors believe that the chromogen interacts with the peptidoglycan-based cell wall structure of bacteria to induce a color change that is even more apparent at infectious levels. It is believed that this interaction occurs to a much greater extent in bacteria than in viruses. Accordingly, although the chromogen may still undergo a color change in the presence of the viruses, it is typically to a much lesser extent. In this manner, the degree of color change of the chromogen may be used in the present invention as a mechanism for differentiating between viral and bacterial conjunctivitis.
Patients with emicizumab concentration of 25-39 μg/mL will continue on their current dose regimen. Patients will be followed for 12 months on current dosing.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes the method of producing lamotrigine of the formula (I)   or its pharmaceutically acceptable salt obtained by acid addition that are used for treatment of patients with the central nervous system disorders. Compound of the formula (II)   where R means CN is subjected for ultraviolet or visible light irradiation in organic solvent at heating followed by if necessarily conversion of the end product to its pharmaceutically acceptable salt by treatment with acid. Invention describes intermediate compounds and the method of pharmaceutical composition preparing also. EFFECT: improved method of producing, valuable pharmacological properties. 13 cl, 15 ex
While the basketball players continue their current basketball training; The 90-minute BFR program will be applied 3 sessions a week for 3 weeks. In the BFR program, biceps curls, triceps curls, shoulder presses, shoulder abduction exercises and sport-specific routine training will be applied. Exercises: 30% of 1 maximum repetition with resistance and 60% of arterial occlusion pressure restricted; Based on previous studies in the literature, the first set will be performed with 30 repetitions and the other three sets with 15 repetitions, a total of 4 sets and a 30-second rest between sets. There will be a 10-minute warm-up exercise before each BFR training and a 10-minute cool-down exercise at the end of the training.
Current treatment options for Chronic Unstable Angina patients with low Ejection Fraction include intensive medical therapy, surgical revascularization, ventricular remodeling, and heart transplantation. Medical treatment alone is problematic because of limited long-term survival. Heart transplantation offers excellent results with a 65.6 % 5-year survival rate; however, the scarcity of donor organs, the need for lifelong immunosuppression and the fact that heart transplantation has been restricted to those without co-morbid medical conditions and relatively restricted to those younger than 65 years of age makes this option impractical for a majority of patients. As a result, coronary artery bypass graft (CABG) surgery is the optimal therapeutic approach and remains superior to medical therapy. Numerous controlled trials of coronary artery bypass grafting in patients with low left ventricular ejection fraction (LVEF), have shown that these are the patients that benefit most from revascularization, especially if symptoms of angina or ischemia are present. This benefit is not only for symptoms, but also on longevity. It is believed that the most important factor for successful surgical recovery may be the viability of revascularized myocardium.
Fractional flow reserve (FFR) is defined as the ratio of mean distal pressure (distal to the target lesion, Pd）to mean proximal pressure (aortic pressure, Pa) in the coronary artery(Pd/Pa) while the maximal hyperemic flow is achieved. Nowadays, FFR-guided PCI is highly recommended for the assessment of physiologic ischemia in intermediate coronary lesions. However, hyperemia with adenosine was an elemental process in FFR examination. Adenosine injection will induce some discomfort, and increase cost expenditure. Based on the clinical and physiologic outcome study, a lot of non-hyperemic indexes had been proposed, and adenosine injection could be waived. Whereas, these novel physiologic indexes are limited to the proprietary software of each vendor, curtailing clinical application. Intracoronary nitroglycerin injection was needed before each FFR assessment. Nitroglycerine will induce an acute drop of Pd/Pa, and this lowest Pd/Pa was determined as NTG-Pd/Pa. NTG-Pd/Pa has a linear relationship with FFR value and has a good diagnostic accuracy to predict FFR≤0.80 in our recent study. There is only one prospective study report on the relationship between NTG-Pd/Pa and FFR. In this study, we aim to evaluate the safety of NTG-Pd/Pa, the repeatability and dose-response of this novel index. Furthermore, we will investigate the diagnostic accuracy of NTG-Pd/Pa, with FFR≤0.8 and Resting full-cycle ratio≤0.89 as ischemic threshold respectively.
Endothelial hyperpermeability is pivotal in sepsis-associated multi-organ dysfunction. Increased von Willebrand factor (vWF) plasma levels, stemming from activated platelets and endothelium injury during sepsis, can bind to integrin αvβ3, exacerbating endothelial permeability. Hence, targeting this pathway presents a potential therapeutic avenue for sepsis. Recently, we identified isaridin E (ISE), a marine-derived fungal cyclohexadepsipeptide, as a promising antiplatelet and antithrombotic agent with a low bleeding risk. ISE's influence on septic mortality and sepsis-induced lung injury in a mouse model of sepsis, induced by caecal ligation and puncture, is investigated in this study. ISE dose-dependently improved survival rates, mitigating lung injury, thrombocytopenia, pulmonary endothelial permeability, and vascular inflammation in the mouse model. ISE markedly curtailed vWF release from activated platelets in septic mice by suppressing vesicle-associated membrane protein 8 and soluble N-ethylmaleide-sensitive factor attachment protein 23 overexpression. Moreover, ISE inhibited healthy human platelet adhesion to cultured lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs), thereby significantly decreasing vWF secretion and endothelial hyperpermeability. Using cilengitide, a selective integrin αvβ3 inhibitor, it was found that ISE can improve endothelial hyperpermeability by inhibiting vWF binding to αvβ3. Activation of the integrin αvβ3-FAK/Src pathway likely underlies vWF-induced endothelial dysfunction in sepsis. In conclusion, ISE protects against sepsis by inhibiting endothelial hyperpermeability and platelet-endothelium interactions.
The present invention relates to a composition for preventing white muscardine of Protaetia brevitarsis seulensis. The composition for preventing white muscardine of Protaetia brevitarsis seulensis includes a Saccharomycessp. strain or culture medium thereof as an effective component. Preferably, the Saccharomycessp. strain is Saccharomyces Cerevisiae. According to the present invention, the composition for preventing white muscardine of Protaetia brevitarsis seulensis is capable of preventing many Protaetia brevitarsis seulensis larvae from having white muscardine during the breeding procedure.